Psoriatic Arthritis
Conference Coverage
How to beat apremilast-induced diarrhea
News
Ixekizumab approved for plaque psoriasis
News
Pushback on Part B drug payment proposal already beginning
News
Home infusion policies called out in ACR position statement
News
ACR’s 2016-2020 research agenda built through consensus
News
Sparse, poor evidence supports fumarates for psoriasis
Only sparse, low-quality evidence supports using fumaric acid esters as a treatment for psoriasis.
News
Anti-Remicade antibodies also cross-react with infliximab biosimilar
Key clinical point: Rheumatology patients with positive antibodies to Remicade should not be switched to infliximab biosimilar (Remsima, Inflectra...
Conference Coverage
Fresh evidence of methotrexate efficacy in psoriatic arthritis
The first-ever trial set up to test the hypothesis that a tumor necrosis factor inhibitor plus methotrexate have synergistic efficacy in psoriatic...
News
Don’t overlook topical tazarotene for psoriasis
Retinoid + superpotent steroid combined lotion is now in a phase III trial.
Conference Coverage
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis
After 60 weeks of continuous ixekizumab therapy, patients with moderate-to-severe plaque psoriasis had PASI 75 scores of 87%.
News
Minimal disease activity criteria in PsA fall short
The minimal disease activity criteria used to identify low disease activity in psoriatic arthritis (PsA) may not be useful as a treatment target...